Abstract | Estrogens mediate profound effects throughout the body and regulate physiological and pathological processes in both women and men. The low prevalence of many diseases in premenopausal women is attributed to the presence of 17β-estradiol, the predominant and most potent endogenous estrogen. In addition to endogenous estrogens, several man-made and plant-derived molecules, such as bisphenol A and genistein, also exhibit estrogenic activity. Traditionally, the actions of 17β-estradiol are ascribed to two nuclear estrogen receptors (ERs), ERα and ERβ, which function as ligand-activated transcription factors. However, 17β-estradiol also mediates rapid signaling events via pathways that involve transmembrane ERs, such as G-protein-coupled ER 1 (GPER; formerly known as GPR30). In the past 10 years, GPER has been implicated in both rapid signaling and transcriptional regulation. With the discovery of GPER-selective ligands that can selectively modulate GPER function in vitro and in preclinical studies and with the use of Gper knockout mice, many more potential roles for GPER are being elucidated. This Review highlights the physiological roles of GPER in the reproductive, nervous, endocrine, immune and cardiovascular systems, as well as its pathological roles in a diverse array of disorders including cancer, for which GPER is emerging as a novel therapeutic target and prognostic indicator.
Introduction 17β-Estradiol is commonly recognized as the predominant female sex hormone, with a critical role in the development of the female reproductive organs and secondary sex characteristics. However, this hormone is also essential for reproductive development and function in males. 1 In addition to the reproductive system, 17β-estradiol has important physiological roles in almost every other area of the body, including the nervous, immune, vascular, muscular, skeletal and endocrine systems. As expected, disruptions in 17β-estradiol signaling, therefore, contribute to multiple disorders, including cancer, cardio vascular diseases, hyper tension, osteoporosis, cognitive and behavioral alterations, neuro degenerative diseases, metabolic disorders (such as obesity and diabetes mellitus) and immune disorders. 2 Our understanding of the widespread physiological effects of 17β-estradiol is complicated by the existence of several types of estrogen receptors (ERs) and multiple modes of cellular signaling mechanisms that span time frames from seconds to hours, or even days. 3, 4 The pathophysiological mechanisms involving ERs are further complicated by a diverse array of 17β-estradiol-mimicking compounds, both synthetic and plant-derived, to which humans are increasingly exposed. 5 In this Review, we provide a brief overview of estrogen signaling and describe the discovery and characterization of its receptors, with particular emphasis on G-proteincoupled estrogen receptor 1 (GPER). We will also discuss studies that have elucidated the functions and importance of GPER in health and disease and those that have revealed the therapeutic potential of small-molecule regulators of GPER activity.
Estrogen receptors
ERα and ERβ The first and best described 17β-estradiol receptor, now called ERα, was identified in the rat uterus in the 1960s. 6, 7 The second, less well-characterized receptor, ERβ, was identified in the rat prostate in 1996. 8 These highly homologous receptors function as ligand-activated nuclear transcription factors that bind cis-acting estrogen response elements in the promoter and enhancer regions of hormonally regulated genes. 9 Both ERα and ERβ, encoded by the genes ESR1 and ESR2, respectively, are soluble receptors that can shuttle between the cytoplasm and the nucleus, but are found predominantly in the nucleus (only ~5% of these receptors are present in the cytoplasm). 4 Highly divergent and sometimes opposing functions for the two receptors have been reported in studies of Esr1 knockout and Esr2 knockout mice, which lack the murine ERα and ERβ protein, respectively. 10 In addition to their effects on gene expression (that is, their genomic effects), these ERs are also associated with rapid cellular signaling (termed non-genomic effects) that are thought to be mediated primarily by membrane-associated forms of these receptors. 11 Although multiple modes of action were suggested for ERs as early as the 1960s, [12] [13] [14] not all effects of 17β-estradiol, particularly the rapid and membrane-associated signaling ■ The estrogen receptors (ERs) include ERα, ERβ and G-protein-coupled estrogen receptor 1 (GPER); their expression and signaling mechanisms are complex and potentially exhibit redundant, independent, synergistic and/or antagonistic actions ■ Estrogenic compounds (selective ER modulators, ER antagonists, selective ER downregulators, phytoestrogens and xenoestrogens) have multifaceted effects on all types of ERs with receptor-specific pharmacological profiles ■ GPER-selective agonists, such as G-1, mediate many salutary effects of estrogen in various tissues and organs with only minor reproductive effects ■ GPER represents an important diagnostic, prognostic and therapeutic target; development of GPER-selective agonists and antagonists could contribute to the diagnosis and treatment of many diseases of 17β-estradiol in premenopausal women are ~0.2-1.0 nmol/l, although it increases by many 100-fold during pregnancy. Local concentrations in specific tissues can be much higher than the plasma values, for example in breast tissue (by 10-20-fold) 38 or in the placenta at term (~12 μmol/l). 39 The hydrophobic nature of these steroids allows them to diffuse passively through cell membranes and reach their intracellular targets, the ERs. 40 A large variety of natural and man-made chemicals also have estrogenic activity (Figure 1) . 5 Estrogenic compounds synthesized by plants (phytoestrogens) include flavo noids, such as coumestans and iso flavones. 41 Synthetic estrogenic compounds (known as xeno estrogens, environ mental estrogens or endocrine disruptors) include many pesticides, herbicides and plastic monomers. 5 Their widespread use results in chronic low-level exposure to these compounds in humans. 42 Although the majority of phytoestrogens and xenoestrogens are believed to exert their physio logical effects through modulation of ERα and ERβ, 43 many of these compounds also activate GPER, including the soy isoflavone genistein, for which serum concentrations up to 500 nmol/l have been measured; 44 nonylphenol; the pesticides dichlorodiphenyl trichloroethane (DDT) and dichlorodiphenyldichloroethylene (DDE); bisphenols, 45 such as bisphenol A (Figure 1 ), which promotes testicular seminoma cell proliferation; 46 the herbicide atrazine; 47 and possibly equol, a nonsteroidal equine estrogen found in premarin 48 that is formed by human gut bacteria as a metabolite of the isoflavone, daidzein. 49 Synthetic 17β-estradiol mimetics are also used extensively in clinical and therapeutic applications. For example, 17α-ethynylestradiol is the predominant estrogen used in female contraceptives. Drugs, such as tamoxifen ( Figure 1 ) and raloxifene, which are used in treatments for breast cancer and osteoporosis, 2 act as ER agonists in some tissues and ER antagonists in others, which led to their designation as selective estrogen receptor modulators (SERMs). 50 By contrast, fulvestrant ( Figure 1 ) is a 'pure' ER antagonist that causes ER degradation and/or downregulation, which led to its designation as a selective estrogen receptor down regulator (SERD). 51 However, some members of SERMs and SERDs can also act as GPER agonists, 17, 33 which complicates the interpretation of the mechanisms of their action and the receptors involved in both physiological and disease conditions. 52 
GPER-selective ligands
Research into the specific activities of GPER has been aided by the discovery of GPER-selective agents. Since the identification of the first GPER-selective agonist G-1 in 2006, a number of reports have examined the disease-related or health-promoting effects associated with GPER activation. Importantly, studies using G-1 (Figure 1 ) at concentrations as high as 1-10 μmol/l showed no notable activity of this agent towards ERα in terms of activating or inhibiting rapid signaling events, 33 estrogen response element-mediated transcription 53, 54 or ERα down regulation. 53 Furthermore, G-1 had no binding activity on 25 other G-protein-coupled receptors 55 or in Gper knockout mice, [56] [57] [58] which provided evidence that G-1 is a ligand highly selective for GPER.
In 2009, the GPER-selective antagonist G15 (Figure 1 ) was identified, 59 followed by G36, a more selective GPER antagonist than G15, identified in 2011. 54 G15 has a similar structure to G-1, 59 and is effective in inhibiting all G-1-mediated effects tested to date, [59] [60] [61] as well as many 17β-estradiol-mediated effects. [59] [60] [61] [62] [63] The core structures of G-1, G15 and G36 have been used to generate several radio actively labeled agents that can be used for imaging and potential treatment of GPER-expressing tumors in vivo. 64, 65 
GPER signaling
Although ERα and ERβ are accepted as the predominant nuclear receptors involved in the genomic effects of estrogen, evidence also indicates that rapid modula tion of cell-signaling pathways occurs via a sub population of ERs located at the plasma membrane (Figure 2 ), 4 which has fueled the speculation about a role of GPER. 66 The localization of GPER, however, seems to be predominantly intra cellular, 33, 67 consistent with reports that describe the constitutive internalization of plasma membrane GPER. 68, 69 Signaling through GPER occurs via transactivation of the epidermal growth factor receptor (EGFR) and involves nonreceptor tyrosine kinases of the Src family. 17 In this mechanism, which is now also accepted for other G-protein-coupled receptors, 70 stimulation of GPER activates metalloproteinases and induces the release of heparin-binding EGF, which binds and activates EGFR, 71 leading to activation of downstream signaling molecules, such as ERK1/2. 72 Moreover, 17β-estradiol-mediated activation of GPER stimulates production of cAMP, 24, 32 intracellular calcium mobilization 33, 73, 74 and PI3K activation ( Figure 2) . 33 Further research in human breast cancer cells suggests that sphingosine kinase 75 and integrin α 5 β 1 76 are intermediates in 17β-estradiol-mediated EGFR transactivation; the latter study suggesting a role for GPER in fibronectin assembly. 76 In addition to the above-mentioned rapid signaling events, GPER also regulates transcriptional activity, albeit indirectly, by activating signaling mechanisms that involve cAMP, ERK and PI3K (Figure 2) . 77 The genes regulated by GPER include FOS, which encodes c-Fos, 28 a protein that forms a heterodimer with various other proteins to form the transcription factor AP-1. In turn, these signaling pathways also activate other transcription factors, such as steroidogenic factor 1, 78 which induce expression of additional genes. 79, 80 GPER in physiology and disease
Reproductive system
The role of 17β-estradiol is best defined in the reproductive system, where this hormone regulates uterine and mammary development and function. Although roles Compounds shown include the three major physiological forms of estrogen (17β-estradiol, estrone and estriol); the anticancer agent tamoxifen and its active metabolite 4-hydroxytamoxifen (which is both a selective estrogen receptor modulator and an agonist for GPER); fulvestrant, a selective estrogen receptor downregulator and agonist for GPER; diethylstilbestrol, a nonselective GPER agonist; the phytoestrogens genistein and coumestrol; and the xenoestrogen bisphenol A. Also shown are G-1 (a selective GPER agonist) and G15 (a selective GPER antagonist).
for GPER are implicated in almost every system of the body (Figure 3 ), conflicting observations have been published particularly in the reproductive system. 34 No clear developmental or functional defects occur in the reproductive organs of Gper knockout mice, [81] [82] [83] [84] whereas Esr1 knockout mice display multiple reproductive defects. 85 Furthermore, in wild-type mice treated with G-1, no change was detected in ductal growth or end bud formation in mammary glands, and no uterine imbibition of water, or proliferative response in the mammary gland or endometrium was observed. 83 However, in another study, G-1 treatment in mice stimulated uterine epithelial proliferation by approximately threefold, compared with a ~15-fold increase in proliferation observed with 17β-estradiol. 59 Importantly, blocking GPER with G15 reduced the 17β-estradiol-mediated proliferative response by ~50%, 59 which suggests that GPER, in part, contributes to this response. Surprisingly, high concentrations of G-1 (1,000-fold greater than those needed to observe a proliferative effect) reduce both 17β-estradiol-mediated uterine imbibi tion of water, and proliferation, through inhibition of ERK1/2 in the stroma and via phosphorylation of serine 118 in ERα. 86 These data suggest that GPER regulates uterine proliferation, indepen dently of ERα, but via a mechanism that might involve crosstalk with the 17β-estradiol-ERα pathway.
In addition to effects on the mammalian uterus, GPER is also involved in the regulation of meiotic arrest in oocytes of the Atlantic croaker and zebra fish. In vitro, 17β-estradiol and G-1 reduced both spontaneous and progestin-induced oocyte maturation in both Atlantic croaker and zebra fish, whereas knockdown of GPER or blockade of GPER with G15 prevented the inhibitory effects of 17β-estradiol, which occur via an EGFRdependent pathway. 62, 87 Further more, GPER (mRNA and protein) expression in granu losa and theca cells of the hamster ovary is regulated by gonadotropins and the estrous cycle, 88 and in this tissue, GPER regulates the 17β-estradiol-mediated stimulation of primordial follicle formation. 89 In ex vivo studies of human myometrium, GPER enhances contractile responses to oxytocin, which suggests a role for GPER in uterine con tractility during labor. 90 Moreover, ERα, ERβ and GPER regulate the proliferative and apoptotic pathways involved in spermatogenesis [91] [92] [93] during male reproductive develop ment. Over all, the roles of GPER in the reproductive system are com plex and require further investigation, particularly in humans.
Nervous system and neuroendocrinology
The effects of 17β-estradiol in the central and peripheral nervous system include maintenance of homeostasis, regulation of synaptic plasticity and cognition, neuroprotection and modulation of pain sensation. Although many of these effects might involve ERα and ERβ, increasing evidence indicates that GPER has multiple roles in 17β-estradiol-mediated neurological functions. GPER (mRNA and protein) expression have been detected throughout the central ( Figure 3 ) and peripheral nervous sys tem of male and female rodents, including in the hippocampus, hypothalamus and midbrain, as well as the spinal cord and dorsal root ganglia. 74, 94, 95 How ever, conflict ing results showing Gper expression in small arterial surface vessels and pericytes in the brain also exist. 81 Both ERα and GPER activate the ERK1/2 pathway in trigeminal ganglion neurons and increase allodynia, indicating a role for these two ERs in temporo mandibular disorder and migraine. 96 Furthermore, in rats, G-1 depolarizes spinal cord neurons, 84 stimulates mechanical hyperalgesia via protein kinase Cξ 97 and mediates visceral hy persensitivity in the absence of inflammation. 17β-Estradiol has many beneficial effects on the brain, including reduction of neuronal loss following stroke, increase in neuronal connectivity and improvement of cognitive performance. 99 GPER has been implicated in 17β-estradiol-mediated effects on cholinergic neurons in the basal forebrain, which suggests that this ER might be an important regulator of cognitive function, particularly in women after menopause. 100 In studies that used immortal ized hippocampal cell lines, GPER (along with ERα) Subpopulations of ERs at the plasma membrane activated by E2 interact with adaptor proteins (adaptor) and signaling molecules such as c-Src, which mediates rapid signaling via PI3K-Akt and MAPK pathways. E2, or selective agonists such as G-1, or selective estrogen receptor downregulators, such as fulvestrant, or selective estrogen receptor modulators, such as tamoxifen, also activate GPER, which is predominantly localized intracellularly. GPER activation stimulates cAMP production, calcium mobilization and c-Src, which activates MMPs. These MMPs cleave pro-HB-EGF, releasing free HB-EGF that transactivates EGFR, which in turn activates MAPK and PI3K-Akt pathways that can induce additional rapid (nongenomic) effects (X), or genomic effects regulating gene transcription. E2-mediated transcriptional regulation may involve phosphorylation (P) of ER or other TFs that may directly interact with ER, or bind independently of ER within the promoters of target genes. Abbreviations: E2, 17β-estradiol; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GPER, G-protein-coupled ER; MMP, matrix metalloproteinase; pro-HB-EGF, pro-heparin-binding-epidermal growth factor; TF, transcription factor.
was implicated in the protective effects of 17β-estradiol against glutamate-induced injury, 63 although in cortical neurons G-1 did not have any effect. 101 How ever, in vivo studies showed that G-1 treatment replicates the effects of 17β-estradiol in promoting neuronal survival following global ischemia in the brain. 102, 103 Altogether, these results suggest that GPER agonists might represent a new therapeutic approach for stroke and chronic neurodegenerative diseases. 104 In the brain, G-1 (like 17β-estradiol) attenuates serotonin receptor signaling in the paraventricular nucleus of the hypothalamus and reduces responses to oxytocin and adrenocorticotropic hormone, which suggests that GPER might have a role in mood disorders. 105 Furthermore, G-1 exhibited antidepressant properties in a mouse model of depression, where it reproduced the effects of 17β-estradiol, which were inhibited by the GPERselective antagonist G15. 59 In primates, GPER contributes to 17β-estradiol-mediated regulation of luteinizinghormone-releasing hormone neurons, which maintain gonadal function and fertility. 106 This effect probably also involves additional mechanisms. 107 However, whereas GPER activation promoted short-latency prolactin secretion, G-1 did not affect the 17β-estradiol-mediated negative feedback inhibition of either luteinizing hormone secretion or lordosis behavior in rats. 108 Studies with Esr1 knockout mice showed that ERα is required for 17β-estradiol-regulated positive feedback control of hypothalamic gonadotropin release, 109 which suggests that the actions of GPER are complex and possibly also require the presence of ERα.
Immune system 17β-estradiol displays multiple effects in the regulation of immune responses, including the development of T cells, 110 Figure 3 | Involvement of G-protein-coupled estrogen receptor (GPER) action in regulation of physiological responses and disease. GPER is implicated in neuroendocrine and cerebral functions, immune cell function, endocrine regulation and metabolism, cardiovascular and kidney function, and reproductive functions. In addition, studies using experimental models of disease and/or human tissue suggest roles for GPER in diseases (shown in red), such as diabetes mellitus, arterial hypertension, proteinuric renal disease, osteoporosis, arthritis, immune diseases, such as multiple sclerosis, and cancer. Collectively, these studies suggest the therapeutic potential of regulating GPER activity as a novel approach for the treatment of these conditions. of inflammation. 111 Studies in Esr1 knockout and Gper knockout mice have shown that GPER, along with ERα, contributes to 17β-estradiol-induced thymic atrophy; 84 ERα mediated the early blockage of thymocyte development, whereas GPER mediated thymocyte apoptosis. Furthermore, in Gper knockout mice engineered to express the pro karyotic lacZ gene under control of the murine Gper promoter, numbers of L-selectin-expressing T cells decreased, consistent with an altered production of these T cells in the thymus. 81 By contrast, other studies using Gper knockout mice did not find any difference in 17β-estradiol-induced thymic atrophy, 113 nor in 17β-estradiol-dependent protective effects on arthritis or bone loss in a model of postmeno pausal rheumatoid arthritis. 114 These findings suggest complex roles for 17β-estradiol and GPER in the immune system (Figure 3) .
Estrogens are increasingly receiving attention as potential anti-inflammatory agents for the treatment of autoimmune diseases, particularly multiple sclerosis. 112 In a mouse model of multiple sclerosis-experimental autoimmune encephalomyelitis (EAE)-knockout of Gper interfered with the protective role of 17β-estradiol. 56 In two studies, treatment with G-1 reproduced the ability of 17β-estradiol to protect against the functional and histological manifestations of EAE through enhancing the immunosuppressive activity of CD4 + Foxp3 + T cells, resulting in upregulation of programmed cell death 56 and inhibition of inflammatory cytokine production by macro phages. 55 These findings suggest that GPER mediates the protective role of 17β-estradiol in multiple sclerosis.
Although the protective effects of G-1 against EAE were absent in Gper knockout mice, 17β-estradiol-mediated effects were partially retained, suggesting that ERα and GPER can activate independent, yet over lapping, mechanisms. Further research showed that the therapeutic effect of ethynylestradiol in established EAE was mediated via GPER, but not via ERα, and possibly involved production of the anti-inflammatory cytokine Il-10. 115 Another study showed that G-1 treatment elicits de novo production of Il-10 in T helper type 17 polarized cells, in vitro as well as in vivo, via an ERK1/2-dependent pathway. 116 Thus, the immunomodulatory effects of G-1, mediated by activation of GPER, indicate that GPER agonists might have novel clinical applications in chronic inflammatory diseases.
Cardiovascular system
Endogenous 17β-estradiol is implicated in sex-specific differences observed in arterial hypertension and cardiovascular disease, 117, 119 as the cessation of 17β-estradiol production following menopause accelerates these conditions. 117 However, the cellular mechanisms and signaling pathways conferring the protective effect of 17β-estradiol are only partially understood. 120 Although ERα and ERβ are implicated in cardiovascular protection mediated by 17β-estradiol, a protective effect of this hormone is also seen in the absence of both receptors. [121] [122] [123] These observations provided the initial evidence for the existence of alternative receptors, such as GPER, and signaling pathways involved in 17β-estradiol-mediated regulation of cardiovascular function.
GPER (mRNA and protein) is expressed in murine 82 and human myocardium, 124 as well as in cultured cardiomyocytes. 125 17β-Estradiol-mediated inhibition of calcium influx and contraction in murine cardio myocytes is indepen dent of ERα and ERβ, 121 and deletion of Gper leads to left ventricular dilatation and elevation of enddiastolic pressure in male, but not female, mice. 126 In patients with myocardial infarction, ischemia-reperfusion injury after reopening of the occluded coronary artery is a critical determinant of outcome and complications, such as arrythmia and heart failure. 127, 128 Myocardial hypoxia resulting from infarction 129 is an important stimulus that upregulates GPER (mRNA and protein) expression in cardiomyocytes. 125 Several groups have independently demonstrated that G-1 treatment after myocardial infarction led to reduced reperfusion-related injury and infarct size and improved contractile function in structurally normal hearts from rodents of both sexes. 124, 127, [130] [131] [132] Similar benefits were also obtained for G-1 treatment in cerebrovascular occlusion-related reperfusion injury in animal models of stroke. 102, 133 Under these conditions, activation of GPER by G-1 resulted in reduced myocardial expression of proinflammatory cytokines (IL-1β, IL-6 and tumor necrosis factor), 132 increased activation of Akt,
134
Erk1/2, 130,134 increased phosphorylation of endothelial nitric oxide synthase (eNOS) 134 and decreased mitochondrial permeability. 131 Some of these cardioprotective effects were blocked by an inhibitor of PI3K. 134 GPER protein is expressed in human endothelial 23, 135 and smooth muscle cells, 58, 136 as well as in intact ar teries (Figure 3) . 136 Expression of GPER in macrophages, 137 which contribute to atherogenesis, also suggests a functional role for GPER in atherosclerosis and the associated inflammation. In human endothelial cells, activation of GPER (but not of ERα) 138 inhibits cell pro liferation, 135 indicating an antiangiogenic role for this ER. In human and rat vascular smooth muscle cells, activation of GPER by either G-1 58, 139 or raloxifene 140 stimulates the ERK1/2 pathway and inhibits proliferation, similarly to the effect of ERα activation in these cells. 140 These findings are in keeping with the antiproliferative effects of 17β-estradiol on vascular smooth muscle cells from Esr1 and Esr2 double-knockout mice. 122 Moreover, the GPER agonists G-1, 58,61,142,143 genistein 144 and fulvestrant 142 ( Figure 1 ) cause vasodilatation in human, porcine and rodent arteries, whereas this effect is blocked by the GPER antagonist G15 61 and is absent in Gper-deficient mice. 58 Elevated vascular resistance is a key feature of arterial hypertension. 119 Gper-deficient mice exhibit a normal mean arterial blood pressure that does not change with age. 82 Infusion of the GPER agonist G-1 markedly lowers blood pressure in normotensive 58 and hyper tensive rats. 61, 145, 146 In rats with hypertensive cardiomyopathy, G-1 treatment ameliorates diastolic dysfunction, reduces cardiac hypertrophy and decreases the size of cardio myocytes. 145 This effect is probably mediated through direct vasodilatory actions of G-1 58, 143, 147 or 17β-estradiol, as this hormone also has vasodilatory effects (which are derived at least in REVIEWS part from GPER, as they are blocked by the GPER antagonist G15). 61 Vasodilatory actions of G-1 involve both nitric oxide-dependent and nitric oxide-independent pathways and have been observed in human, pig and rat arteries. 58, 61, 143, 146 Phosphorylation of eNOS as a result of GPER activation might contribute to this response. 49, 134 At least some of the vaso protective effects mediated by GPER are probably the result of interference with endothelial cell dysfunction-a vascular abnormality common to hy pertension and coronary artery disease. 118, 148 Altogether, these data indicate a central regulatory role for GPER in cardiovascular function and suggest that GPER ago nists have potential roles in the treatment of vascul ar and myocardial disease in both men and women.
Renal system Endogenous 17β-estradiol is also implicated in the sexspecific differences in renal disease. 117 GPER is expressed at high levels in renal tubules, 95 as well as in renal epithelial cells (Figure 3) . 68 In humans, the GPER locus is associated with low-renin hypertension, 149 which leads to kidney injury and vascular dysfunction (the latter abnormality is ameliorated by G-1 treatment). 146 Endothelial cell dysfunction is also present in animals with glomerulo sclerosis, which leads to proteinuria due to loss of glomerular filter function. In hypertensive rats, GPER activation reduces proteinuria and improves creatinine clearance despite continued hypertension. 150 These findings suggest a renoprotective role for GPER agonists in hypertensive nephropathy.
Pancreatic function and glucose metabolism
The increased prevalence of obesity, insulin resistance and diabetes mellitus after menopause indicates a protective role for endogenous 17β-estradiol in premenopausal women. 151, 152 These protective effects are largely attributed to signaling via nuclear ERα, 153, 154 as its deletion results in obesity and insulin resistance. 151, 155 However, other forms of ERα signaling are also involved in metabolic diseases; 154, 156 for example, insulin secretion mediated by 17β-estradiol occurs through rapid signaling via membrane-bound ERs. [157] [158] [159] Although ERα and ERβ individually affect insulin action, 151, 155 mice deficient in GPER develop insulin resistance and obesity in a sexdependent manner. 58, 82, 160 GPER activation also has antiinflammatory properties in pancreatic islets through attenuating the effects of proinflammatory cytokines 161 that are important for maintenance of metabolic function (Figure 3) . 162 The protective, antidiabetic effects of 17β-estradiol in islet cells seem to involve activation of both membrane-bound ERα and GPER 57, 163, 164 and might also be induced by GPER agonists, such as genistein. 165 GPER is expressed in whole adipose tissue in humans and rodents, 58, 166 as well as in the human liver, [18] [19] [20] 22, 23 key target organs of insulin resistance. 162 However, the role of GPER in 17β-estradiol-mediated metabolic protection is not clearly defined. GPER is expressed in the pancreatic islets of mice 57, 82, 161, 163, 164 and humans, 163 and in female mice it maintains normal metabolic function. 82 GPER deficiency results in a reduction in insulin secretion (stimulated by 17β-estradiol, G-1 and glucose) from the pancreas without affecting the morphology of pancreatic β-cells, which suggests that GPER has a key role in maintaining the metabolic functions of insulin in mice 82, 167 and humans. 168 Furthermore, the protective effect of 17β-estradiol on survival of pancreatic β-cells in a mouse model of type 1 diabetes mellitus is absent in GPERdeficient animals. 57 Whether GPER contributes to peripheral insulin resistance is currently not known. However, expression of GPER has been reported in human skeletal muscle, 56, 81, 161, 163 and is unaffected by menopause. 169 Bone growth and chondrocyte metabolism Bone and articular cartilage are hormone-sensitive tissues, 170 and serum 17β-estradiol levels inversely correlate with the risk of hip fracture in both women and men. 171 Perhaps the best evidence of a role for endo genous 17β-estradiol in overall bone health and formation of trabecular bone in particular is the postmenopausal onset of osteoporosis. The bone-preserving effects of estrogen therapy, especially with SERMs, 172 which act as GPER agonists, indirectly suggest a role for GPER in bone metabolism ( Figure 3 ). Endogenous 17β-estradiol also plays an important role in bone metabolism in men, since lack of 17β-estradiol owing to aromatase deficiency 173 or mutations in ESR1 174 in men lead to osteopenia, enhanced bone remodeling through increased bone resorption and osteoclast activity and suppression of bone growthplate closure. 175 Although part of this effect is mediated through ERα and ERβ, 172 several avenues of research now suggest a role for GPER in bone and cartilage metabolism. In bone, GPER is expressed in osteocytes, osteoclasts and osteoblasts, 176, 177 and is also detected in chondrocytes, 176, 178 the differentiation of which is regulated by GPER. 178 In addition, GPER also controls bone growth, as illustrated by several models of GPER deficiency, albeit in a sex-dependent manner (Figure 3) . Gper deficiency inhibits bone growth in female mice;
82 similar results were reported in ovariectomized, estrogen-treated animals, 113 suggesting a role for GPER in estrogen-induced bone growth and development. By contrast, GPER-deficient male mice show increased femur size, BMD, trabecularization and cortical bone thickness. 160 Tamoxifen, a GPER agonist, decreases tibia length independently from ERα or ERβ. 52 Although in vitro studies and clinical trials with SERMs show beneficial effects on bone structure in postmenopausal women, 172 the role of GPER in bone and chondrocyte metabolism in humans is still not clear and warrants further study.
GPER in cancer growth and metastasis
17β-Estradiol is a critical mediator of breast carcinogenesis and is involved in a number of other hormonesensitive cancers. Normal breast tissue is highly sensitive to 17β-estradiol, which stimulates proliferation of this tissue during puberty, the menstrual cycle and pregnancy; thus, the majority of breast cancers are highly responsive to 17β-estradiol and utilize 17β-estradiol signaling pathways in cancer initiation, progression and metastasis. 179 This understanding has led to the development of various REVIEWS cancer therapies that target 17β-estradiol signaling, the most widely used of which is tamoxifen. 180 Antiestrogen therapy has been extended to include SERDs (such as fulvestrant), aromatase inhibitors (for postmenopausal women) and other SERMs (such as raloxifene). 50 Many of these agents, particularly tamoxifen and fulvestrant, are also GPER agonists and have complex physio logical and therapeutic actions. For example, long-term 17β-estradiol deprivation in the weakly metastatic human breast cancer cell line MCF-7 increased expression of GPER, 181 whereas tamoxifen treatment of these cells stimulated proliferation via GPER-mediated transactivation of EGFR. 182 GPER protein is expressed in ~50% of all breast cancers (Figure 3) , regardless of their ER status, 183 although conflicting results have been reported regarding coexpression of GPER and human epidermal growth factor receptor 2 (HER2). [183] [184] [185] Nevertheless, in general, GPER protein expression in breast cancers correlates with clinical and patho logical bio markers of poor outcome. High levels of GPER protein expression in samples of human breast cancers also correlate with increased tumor size and metastasis. 183 Importantly, in patients treated only with tamoxifen, GPER protein expression was increased and survival was markedly reduced in patients with initial GPER-positive tumors, suggesting that patients with breast cancer who have high GPER protein expression should not be treated with tamoxi fen alone. 186 In addition, GPER is widely expressed in cancer cell lines and primary tumors of the breast, 17, 18, 33, 187 endo metrium, [188] [189] [190] ovaries, 47, 53, 191 thyroid, 190 lung, 192 prostate, 193 testicular germ cells 194 and the brain (E. R. Prossnitz, unpublished work). In cell lines of thyroid, ovarian, endometrial and breast cancers, stimulation of GPER with 17β-estradiol 53, 190, 195 or other estrogenic compounds, such as atrazine, 47 genistein, 190 bisphenol A 46, 196 or tamoxifen 195 activates a signaling mechanism that typically promotes proliferation, although inhibition of proliferation has also been reported. 73 In particular, genistein can stimulate MCF-7 cell growth via induction of acid ceramidase, which occurs through a GPER-dependent mechanism. 197 In endometrial cancer 198 and ovarian cancer, 199 high levels of GPER expression also predict poor survival, whereas among postpubertal testicular germ cell tumors, GPER was highly expressed in intratubular germ cell tumors, seminomas and embryonal carcinomas, with little ex pression in teratomas. 194 Importantly, treatment of the ERα-negative human breast cancer cell line SKBr3 with 17β-estradiol or tamoxifen increased the expression of several transcription regulators (including c-Fos) and cytokines (particularly connective tissue growth factor, which promotes cancer cell proliferation and migration). 200 These data indicate that tamoxifen treatment might have a cancer-promoting effect through GPER. In support of this view, endometrial GPER protein expression also correlated with tamoxifeninduced uterine pathology, including bleeding and abnormal endometrial thickening, 201 which correlates with an increased incidence of endometrial cancer. 202 The overall role of GPER in breast cancer progression is complex. In addition to the effects on epithelial cells, GPER is implicated in 17β-estradiol-mediated activation of cancer-associated fibroblasts, which promote tumor cell proliferation and meta stasis through direct association of GPER with chromatin. 203 GPER expression was induced in breast cancer cells under hypoxic conditions, which also suggests a cancer-promoting role for this ER, including a role in hypoxia-induced angiogenesis. 125 However, G-1 inhibits endothelial cell proliferation, which indirectly suggests that GPER activity also interferes with angiogenesis. 135 Despite these conflicting data on the role of GPER in cancer, target ing its activity represents an important new approach for cancer therapy.
Conclusions
The salutary effects of estrogens are well-established in many diseases, and selective activation of GPER by G-1, phytoestrogens, SERDS or SERMS can reproduce the bene ficial effects of 17β-estradiol. The pace of research into the physiological and pathological functions of GPER has been accelerating over the past 5 years, and potential roles for GPER have now been identified in almost every system of the body. Thus, GPER-selective agents that mimic the beneficial effects of 17β-estradiol without its associated feminizing or other adverse effects could re present an important new family of drugs.
In addition, GPER-specific antagonists could be developed as important additions to the armamentarium of drugs used to treat estrogen-sensitive cancers and other diseases in which estrogen signaling is important. In this regard, the potential contribution of GPER-mediated signaling to the effects of existing clinically approved drugs, such as tamoxifen and fulvestrant, must be considered. GPER-mediated effects should also be taken into account in the future development of SERMs and SERDs. In addition, further research is required to determine to what extent the physiological effects of 17β-estradiol involve GPER signaling and the precise roles of nonselective estrogen receptor ligands in health and disease. The co-dependent, redundant and independent aspects of 17β-estradiol signaling through ERα, ERβ and GPER are likely to be very complex and specific to particular cell types, tissues, ligands and diseases. The data available to date nevertheless pose interesting questions about the therapeutic potential of specifically targeting GPER in disease.
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